Two Sigma Advisers
ABOS icon

Two Sigma Advisers’s Acumen Pharmaceuticals ABOS Stock Holding History

Two Sigma Advisers’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-421,800
Closed -$890K – 11
2025
Q4 		$890K Sell
421,800
-1,800
-0.4% -$3.57K ﹤0.01% 1542
2025
Q3 		$724K Sell
423,600
-2,700
-0.6% -$3.74K ﹤0.01% 1612
2025
Q2 		$495K Sell
426,300
-37,400
-8% -$40.2K ﹤0.01% 1758
2025
Q1 		$510K Sell
463,700
-35,400
-7% -$50.6K ﹤0.01% 1768
2024
Q4 		$858K Buy
499,100
+30,000
+6% +$72.2K ﹤0.01% 1541
2024
Q3 		$1.16M Buy
469,100
+77,000
+20% +$209K ﹤0.01% 1340
2024
Q2 		$949K Buy
392,100
+175,100
+81% +$557K ﹤0.01% 1578
2024
Q1 		$879K Buy
217,000
+87,300
+67% +$329K ﹤0.01% 1642
2023
Q4 		$498K Buy
129,700
+109,612
+546% +$325K ﹤0.01% 1925
2023
Q3 		$83.4K Buy
+20,088
New +$124K ﹤0.01% 2234

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Two Sigma Advisers's ABOS Position: Q1 2026 in Review

Two Sigma Advisers sold out of Acumen Pharmaceuticals (ABOS) in Q1 2026, closing a stake of 421,800 shares — an estimated $890K sold.

Two Sigma Advisers first reported a position in ABOS in Q3 2023 and held it in 10 quarters. The position peaked at $1.16M in Q3 2024. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Two Sigma Advisers reported no remaining Acumen Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 421,800 Acumen Pharmaceuticals shares in Q1 2026, an estimated $890K.
  • Two Sigma Advisers first reported a position in Acumen Pharmaceuticals in Q3 2023 and held it in 10 quarters.
  • Two Sigma Advisers's Acumen Pharmaceuticals position peaked at $1.16M in Q3 2024.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.